GP2013

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
012320132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar… (More)
  • figure 1
  • figure 2
Is this relevant?
2017
2017
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2017
2017
BACKGROUND GP2013 is a rituximab biosimilar developed to stringent development guidelines, including non-clinical and preclinical… (More)
Is this relevant?
2014
2014
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report… (More)
  • figure 1
  • figure 2
  • table I
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
OBJECTIVE To review current evidence concerning pharmacology of biosimilar candidates to be used in rheumatology. METHODS A… (More)
Is this relevant?
2013
2013
Regulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A thorough… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?